Immunotherapy treatment with ipilumimab after resection of high-risk melanoma improves overall survival compared to no treatment. In high risk melanoma lesions where a cutaneous melanoma has spread to local lymph nodes, despite surgical resection, only about 45% of patients will not have the melanoma come back within 4 years. Currently, there are no great medical… Read more »
Immune therapy treatments first were approved for treatment of melanoma. In fact, the FDA recently approved combination of two immunotherapy drugs as initial treatment of melanoma. Recently, these same immune therapies have been approved for other cancers in the “second line setting, ” which means that initial chemotherapy is not working any longer. First, immune… Read more »
